R&D

Pipeline

AbilityPharma has investigated the antiproliferative activity in a series of compounds, in in vitro models with several tumor cell lines. The mechanism causing the antiproliferative effect has also been characterized in several candidates.
 
ABTL0812, the most advanced asset, has finished with very positive results a phase 2a clinical trial as first-line therapy in endometrial cancer and in squamous NSCLC in combination with paclitaxel and carboplatin. The study included leading institutions in Spain and France (Vall d’Hebron Institut d’Oncologia – VHIO, Institut Gustave Roussy, Centre Léon Bérard).
 
AbilityPharma's next goal is to conduct an international multicenter, double-blind, placebo-controlled phase 2b/3 clinical trial in pancreatic cancer to investigate ABTL0812 in combination with FOLFIRINOX chemotherapy. The study will include reference centers in Spain, France, United States and Israel.





 
 
 

LATEST NEWS

28.12.2020

Press Release

The Chinese pharmaceutical company SciClone joins the capital of AbilityPharma with an investment commitment of three million dollars + info
16.12.2020

Press Release

The antitumoral drug ABTL0812 shows promising results against neuroblastoma + info
05.11.2020

Press Release

AbilityPharma receives the approval from the FDA and the AEMPS to start the clinical trial of its molecule against pancreatic cancer in the US and Spain + info
22.10.2020

Press Release

AbilityPharma receives a 1.6 million euro grant from the FDA and opens a crowdfunding campaign in Capital Cell + info
22.09.2020

Press Release

ABILITYPHARMA PRESENTS THE RESULTS OF A NEW FIRST-LINE TREATMENT FOR ENDOMETRIAL CANCER + info
09.06.2020

Press Release

AbilityPharma publishes full characterization of mechanism of action of ABTL0812, a Phase II clinical inducer of cytotoxic autophagy in cancer cells, in Autophagy journal + info
25.03.2020

Press Release

AbilityPharma awarded €5 million from the Horizon Europe EIC Accelerator Pilot Program to conduct a Phase 2b clinical trial with ABTL0812 in patients with advanced pancreatic cancer + info
12.09.2019

Press Release

AbilityPharma rises € 3.5 million in a financing round to complete the current oncologic phase 2 clinical trial and license ABTL0812 to an international pharmaceutical company + info
31.05.2019

Press Release

Ability Pharmaceuticals Announces the Presentation of the First Results of ABTL0812 as First Line in Patients with Endometrial or Lung Cancer at 2019 ASCO Annual Meeting + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
NEORG